05.24.22
Stratum Nutrition, through its parent company ESM Technologies, LLC recently received Notices of Allowance for two different patents: one in Europe and the other in Canada.
One patent, “Methods for Treating NF-kB Dysregulation in a Host in Need Thereof Using Eggshell Membrane Compositions,” was first issued in the U.S. in 2019 (US 10,328,104) and has recently been allowed by the European Patent Office. This invention deals with a host of conditions and diseases related to NF-kB dysregulation, including: pulmonary, gastrointestinal, cardiovascular, and nervous system.
The other patent, “Method for Evaluating Articular Joint Therapeutics” was first issued in the U.S. in 2018 (US 9,983,214) and has recently been allowed by the Canadian Intellectual Property Office. This invention deals with a clinical trial design using the cartilage degradation biomarker CTX-II to evaluate articular joint therapeutics for chondroprotective efficacy. Both patents are still pending in multiple additional jurisdictions.
“We are excited to extend our patent protection to additional geographies,” said Kevin Ruff, senior director of scientific and regulatory affairs at Stratum. “This is particularly true for our CTX-II clinical model patent, which has now been allowed in the U.S., Europe, Canada, Japan, and several other countries. We have used this patented model in multiple clinical trials to demonstrate that our flagship ingredient, NEM brand eggshell membrane, helps to protect cartilage in exercising individuals.”
One patent, “Methods for Treating NF-kB Dysregulation in a Host in Need Thereof Using Eggshell Membrane Compositions,” was first issued in the U.S. in 2019 (US 10,328,104) and has recently been allowed by the European Patent Office. This invention deals with a host of conditions and diseases related to NF-kB dysregulation, including: pulmonary, gastrointestinal, cardiovascular, and nervous system.
The other patent, “Method for Evaluating Articular Joint Therapeutics” was first issued in the U.S. in 2018 (US 9,983,214) and has recently been allowed by the Canadian Intellectual Property Office. This invention deals with a clinical trial design using the cartilage degradation biomarker CTX-II to evaluate articular joint therapeutics for chondroprotective efficacy. Both patents are still pending in multiple additional jurisdictions.
“We are excited to extend our patent protection to additional geographies,” said Kevin Ruff, senior director of scientific and regulatory affairs at Stratum. “This is particularly true for our CTX-II clinical model patent, which has now been allowed in the U.S., Europe, Canada, Japan, and several other countries. We have used this patented model in multiple clinical trials to demonstrate that our flagship ingredient, NEM brand eggshell membrane, helps to protect cartilage in exercising individuals.”
